Inovio Pharmaceuticals, Inc. (INO)
10.46 -0.12 (-1.13%)
Before hours: 9:12AM EST
| Previous close | 9.72 |
| Open | 9.80 |
| Bid | 10.36 x 2900 |
| Ask | 10.40 x 800 |
| Day's range | 9.50 - 10.68 |
| 52-week range | 3.14 - 33.79 |
| Volume | 17,794,201 |
| Avg. volume | 11,541,222 |
| Market cap | 2.164B |
| Beta (5Y monthly) | 1.08 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -1.32 |
| Earnings date | 09 Nov 2020 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 12.29 |
- PR Newswire
INOVIO Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares
INOVIO Pharmaceuticals, Inc. (Nasdaq: INO), a biotechnology company focused on bringing to market precisely designed DNA medicines to treat and protect people from infectious diseases, including COVID-19, cancer and HPV-associated diseases, today announced the closing of its previously announced underwritten public offering of 20,355,000 shares of its common stock, which includes 2,655,000 shares sold pursuant to the underwriters' exercise in full of their option to purchase additional shares, at a price to the public of $8.50 per share. The gross proceeds to INOVIO from the offering, before deducting underwriting discounts and commissions and offering expenses, were approximately $173 million.
- Simply Wall St.
What Is The Ownership Structure Like For Inovio Pharmaceuticals, Inc. (NASDAQ:INO)?
If you want to know who really controls Inovio Pharmaceuticals, Inc. ( NASDAQ:INO ), then you'll have to look at the...
- PR Newswire
INOVIO Announces Pricing of Public Offering of Common Stock
INOVIO Pharmaceuticals, Inc. (Nasdaq: INO), a biotechnology company focused on bringing to market precisely designed DNA medicines to treat and protect people from infectious diseases, including COVID-19, cancer and HPV-associated diseases, today announced the pricing of an underwritten public offering of 17,700,000 shares of its common stock at a public offering price of $8.50 per share. In addition, INOVIO has granted the underwriters a 30-day option to purchase up to an additional 2,655,000 shares of common stock at the public offering price, less underwriting discounts and commissions. Gross proceeds to INOVIO from the offering are expected to be approximately $150.5 million, before deducting underwriting discounts and commissions and estimated offering expenses, but excluding any exercise of the underwriters' option. All of the shares are being sold by INOVIO.
